Aventis Pharma. Aventis Pharma. Prescription drugs Aventis Pharma. Vaccines Aventis Pasteur. Therapeutic proteins Aventis Behring. Diagnostics Dade Behring. Aventis Pharma. Key Figures. 92, 500 employees – 80% in Pharma 16 Bn€ Pharma sales – 5th in top 10
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Aventis Pharma Prescription drugs Aventis Pharma Vaccines Aventis Pasteur Therapeutic proteins Aventis Behring Diagnostics Dade Behring Aventis Pharma
Key Figures • 92, 500 employees – 80% in Pharma • 16 Bn€ Pharma sales – 5th in top 10 • Strong & growing US presence with >35% sales • 19,000 member sales force • 16.8% R&D expenditure; 6500 scientists & technicians worldwide • 15% of R&D expenditure dedicated to alliances; about 50 major biotech collaborations; about 250 academic collaborations
* Gene Therapy Drug Innovation & Approval (R&D)Disease Groups supported by powerful technology platforms • ~6500 scientists & technicians worldwide - Oncology, - Infectious Diseases - Neurodegenerative Diseases, (Parkinson & Alzheimer), Asian Drug Devt Ctr European Drug Devt Ctr US Global and US Drug Devt Ctr • - Immunology platform - Respiratory diseases - RA - CNS JAPAN FRANCE GERMANY • CV- Metabolic Diseases, - Osteoarthritis, Thrombosis
CDG Airport SEINE ST DENIS Romainville HAUTS DE SEINE PARIS Vitry-Alfortville Croix de Berny VAL DE MARNE ESSONNE Evry 5 km Drug Innovation & Approval in France • Paris Research Centre • European Drug Devt Centre • ~2800 scientists & technicians
Target Selection Lead Identification Candidate Identification Preclinical Candidate Identification PhI / IIa PhIIb PhIII Regulatory Review Integrated Data and Knowledge Management New drug discovery technologies Functional Genomics TechnologiesDNA chips Proteomics, cellular & animal models.. Lead Identification TechnologiesMedChem, ChemBiol, Structural Genomics and Biology…. Technologies for Exploratory DevelopmenteADMET, TGX, PGX, Biomarkers…. Technologies for Global Rapid submissionse-submissions…..
Metabolism OncologyCNS / ND Cardiovascular Rheumatoid Arthritis Osteoarthritis - DJD Respiratory Diseases Anti-Infectives Immunology platform Aventis Genomics Centers DiseaseBiologyPlatforms GenomicsTechnologyPlatforms External Collaborations & Networks External Collaborations & Networks Targets relevant to disease Integration of Genomics Technologies &Disease Biology Platforms
Key Challenges • The post-human genome sequence race • functional genomics • proteomics • protein structure prediction • re-thinking chemical approaches • re-thinking clinical development • Continuous integration of technologies (alliances and partnering), information and knowledge (knowledge networks) • Availability of skilled work force (right skill-set and mind-set)
Post-doc Opportunities in Aventis Pharma, France In partnership with the European Commission: 12 Marie Curie Industry Host Fellowships for a 2 year period. • Parkinson’s Disease Gene Targets (3 positions) • Molecular Modeling and High Throughput Medicinal Chemistry (3 positions) • From Protein-Protein Interactions (yeast 2H) to Lead Discovery Process (3positions) • Bio-Informatics in Toxicogenomics (1 position) • Cardiovascular Gene Therapy (1 position) • Adenoviral Vector-based system for Functional Genomics (1 position) Immediate Starting Date
Post-doc Opportunities in Aventis Pharma, France In partnership with the European Commission The position are open to members of the E.C. or resident of associated countries for more than 5 years. The age limit at the time of selection is 35 years old. Austria, Belgium, Bulgaria, Czech republic, Denmark, Estonia, Finland, Germany Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Liechtenstein Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Republic of Cyprus, Romania Slovakia, Slovenia, Sweden, Spain, United Kingdom However French citizens are ineligible as well as those who have been resident in France for more than 12 out of the last 24 months.
Post-doc Opportunities in Aventis Pharma, France Coming soon 9 post-doctoral positions • Statistics for Pharmacogenetics • Kinases in Oncology and Neurodegenerative diseases • Gene Transfer in Angiogenesis • Genomic Studies for the glial-neuronal interactions
Post-doc Opportunities in Aventis Pharma, France • Project Team • Networking • Publications/patents • Confidentiality • 250 KF/year (38KEuros/year) • Social security included • 26 + 12 days holiday
Post-doc Opportunities in Aventis Pharma, France Come and join us on the Aventis stand to learn more about our post-doctoral opportunities ! email@example.com